Clinical trial NCT04974307: Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision
Official title: Pilot Study of an Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: CLN3-related Disorders
Non-CLN3 Related Low Vision
Keywords: OrCam
Legal blindness
Safety
Feasibility
Efficacy
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 2021-07-23
Enrollment: 11
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Background:

CLN3 involves vision loss observed around the preschool years, with eventual progression to blindness within 1-3 years. Researchers want to test an assistive device that may help children with CLN3 or with non-CLN3 related blindness.

Objective:

To learn if it is safe, easy, and useful for children with CLN3 or with non-CLN3 related blindness to use the OrCam.

Eligibility:

People aged 6-18 years who have either CLN3-related disease or non-CLN3 related blindness.

Design:

Participants will be screened with the following:

Medical history

Physical exam

Family history

Eye exam and vision tests. They will get eyedrops to dilate their eyes.

Psychological and neurocognitive tests. They will be asked questions and observed for how they do various tasks, such as talking, playing, writing, drawing, and solving problems.

Hearing tests. They may wear headphones or earplugs. Electrodes may be taped to their head.

Blood samples

Skin biopsy, if needed

Cheek cell, saliva, or urine samples

The OrCam is the size of and weighs about half as much as a pack of gum. It is attached to eyeglass frames by magnets. Participants will do tasks before and after they have been trained on the OrCam. They will do these tasks without or with using the OrCam.

Participants will be given an OrCam to use for 1 week or 1 month. They will have check-in sessions with the study team.

Participants and/or their caregivers will be asked about abilities, behaviors, social skills, learning methods, intelligence, and health-related quality of life.

Participants samples may be used for genetic testing and/or to make a type of stem cell.

Participation will last for 1-5 weeks.

Detailed description: Study Description:

This is a pilot study of an augmentative visual device, OrCam MyEye 2 (OrCam), in pediatric individuals with CLN3-related conditions or low vision. We hypothesize that, given the relatively simple design and operating procedure of the device, the use of the OrCam by study participants will be safe and feasible. We also hypothesize that the device will enhance their ability to obtain visually based information.

Objectives:

Primary: Assess the safety and feasibility of OrCam use by children with CLN3 or low vision.

Endpoints:

Primary:

1. Adverse events during the use of OrCam
2. Feasibility test
3. Feasibility questionnaire

The assessment periods will be 1 week at study site.

Eligibility criteria: INCLUSION CRITERIA:

To participate in the screening portion of this study, an individual must meet all of the following criteria:

1. Have a diagnosis or suspected diagnosis of any genetically based condition causing low vision to the level specified in criteria 2.

   If the genetic condition is CLN3-related, the individual must have one of the following:
   * a. Two CLN3 pathogenic variants, OR
   * b. One CLN3 pathogenic variant AND

     * i. clinical presentation suggestive of CLN3, OR
     * ii. characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits).
2. Have an estimated visual acuity in the better seeing eye \< 20/200, without the use of an assistive or augmentative device.
3. Is between 6 to 18 years of age.

To participate in the intervention/device use portion of this study, an individual must meet the above screening criteria and the following criteria:

* Have an appropriate cognitive developmental ability to participate based on Investigators screening assessment.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

* Has any of the following auditory dysfunctions: non-reversible or non-correctable hearing loss, tinnitus that is chronic or occurring daily, auditory hallucinations that occur daily.
* Uses an optic-to-audio assistive device at the time or within 3 months of screening and enrollment.
* Is unable to travel to the NIH because of medical condition for required in-person portions of the study.
* Is unable to comply with or have medical conditions that would potentially increase the risk of participation.

Primary outcomes:
measure: Participants With Adverse Events
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Institutes of Health Clinical Center
state: Maryland
Study officials:
affiliation: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
name: An N Dang Do, M.D.
role: PRINCIPAL_INVESTIGATOR
References: